wmw<m45$u4<zmmpxm
`
`.2\.\\S
`
`
`
`,..NN
`
`‘>mOEmE
`
`_-um_.._.-g
`
`
`w.§<moomm
`
`zOCfiUjmud
`
`cm
`
`,wmmfimficgu4<zmmpz_
`
`mm>mmm
`
`5%
`
`mmNEwa_
`
`,
`
`,
`
`.
`
`mommmooE.,,VOE
`a_.
`
`
`
`
`
`
`
`
`
`
`

`

`50
`
`6'6
`
`7‘
`TEST FOR AT
`, PERFORM AT LEAST ‘
`'
`
`
`
`LEAST ONE. TARGET FRDNI A RIDLDGICAL
`H SAMPLE DF DISEASED NIVALDIID
`
`
`
`,
`
`.
`
`52
`
`OTHER NDLIRLECLA TTs
`
`
`
`
`
`
` ' 60.
`
`
`
`DETERMINE WHETHER ONE OR MORE
`TARGETS EXHIBITA CHANGE IN
`.
`_
`_
`' EXPRESSION COMPARED TO A REFERENCE
`
`FOR A SPECIFTC TARGET
`'
`
`
` 369370R>
`
`CELLS +3505? >
`,
`'
`
`STATNTNGFOR {} .
`TARGET
`,
`"
`
`
`V IDENTIFY UP DR DOWN REGULATION BY
`
`
`
`WHETHER FOLD CHANGE IN EXPRESSION
`:
`_ FOR TARGET RELmIgBIaNDRMAL Is SIGN.
`
`IDENTIFY AT LEAST ONE NONFDISEA-SE
`
`SPECIFIC AGENT THAT INTERACTS WITH
`ONE OR MORE TARGETS EXHIBITING A
`
`CHANGE IN EXPRESSION
`
`
`
`
`
`
`.. 70
`L
`
`
`
`
`PROVIDE PATIENT PROFILE RPORT
`CONTAINING TESTAND PROPOSED
`THERAPYI’AGENT
`
`~30
`
`FIG.2
`
`

`

`
`
`j
`
`;
`
`
` HYSIOIAN INFORMATION
`PATIENTINFOMATION
` IAILTIII
`
`
`I SOME DOCTOR, MUD.
`
`MOLECULAR NAME SAMPLE PATIENT
`:
`1234 E. SOUTH ST.
`PROFILING
`LISA RANT
`
`
`
`
`
` SSNII‘. 123—456789
`INSTITUTE
`
`
`
`
`,
`.VER1.0.2:425-0
`REPORTINFORATION
`
`
`
`DATE SPECIMEN RECEIVED: 02002000 DATE REPORTED:02I09I2006 0000 00. MP-IIIMMMI
`
`DATE SPECIMEN COLLECTEIIM HOST MEDICAL CENTER: 00242000
`SPECIAL STUDIES ’ RESULTS AND INTERPRETATION
`
`TUCSON, AX 12345
`
`480423-4567
`
`INTERPRETATION:
`
`REVIEW OF PATHOLOGY SLIDES (RECEIVED FROM MAIN HOSPITAL IIICSON AZ ONE PARAFFIN BLOCK LABELED
`MIN-123 AND FROZEN TISSUE)
`
`PELVIC AND RETROPERIIONEALTUMOR: INFLAMMATOR‘I’MYDFIBROLASTIC TUMOR.
`
`100
`
`108
`104
`202
`- POSSIBLEAGENTSTHATMIGHTINTE ICTWITHCANDIDATEGfiTARGETS-i
`
`//
`
`CANDIDATE TARGET
`ASSAY“
`NFKBIA
`MICROARRAY
`~ C—KIT
`‘IHC
`PDG‘FRA
`MICROARRAY
`GART
`MICRDARRAY
`VDR
`MICROARRAY
`ADA
`MICROARRAY
`TOPI
`MICROARRAY
`HIFIA
`MIGROARRAY
`DNMTI
`MICRDARRAY
`*IHG : IMMUNOHISTOCHEMISTRY
`
`SIGNIFICANT RESULT
`(INCREASED 1.78)“
`(INCREASEDT‘Z, 93%)
`(INCREASED 4.74)“
`(INCREASED IND)“
`(INCREASED 37.30)“
`(INCREASED 5.P26)
`(INCREASED 278)“
`[INCREASED 4NI)“I
`(INCREASEDIIII)“
`
`\
`
`POSSIBLE AGENT S
`VELCADE
`GLEEVEC, SUTENT
`GLEEVEC, SORAFENIB, SUTENT
`ALIMTA
`CALCIIRIOL
`PENTOSTATIN
`TOPOTECAN, CAMPTOSAR (CPIII)
`AVASTINI SORAFENIR SUTENT
`VIDAZA (S-AZACYTIDINE)
`‘
`
`,
`
`I
`
`'
`
`** INCREASED OR DEC‘REASED ARE RELATIVE TO NORMAL CONTRLS.
`
`FIG.3A
`
`

`

`
` PHYSICIAN INFORMATION
`
` PATIENT INFORMATION
`
`
`SOME DOCTOR, MD.
`NAME: SAMPLE PATIENT
`
`
`SEX: FEMALE
`MOLECULAR
`.
`1234 ESOUTH ST.
`
`
`. Agfgfigg‘mfl
`SESTNTT TQAIEET-STRQ
`PROFILING
`
`
`
`

`-

`INSTITUTE
`
`
`REPORTINEQRNATION
`VER 1 0.242505 .
`
`DATE SPECIMEN RECEIVED 02012000 DATE REPORTED. 02H002000 CASEND MRTNN05040
`
`
`
`DATE SPEIMEN COLLECTED AT HOSTMEDICAL CENTERO012402000
`
`
`
`.
`
`, SPECIAL STUDIES
`RESULTS AND INTERPRETATION
`ADVANCED IMMUNOHISTOCHEMICAL ANALYSIS:
`ENE EXPRESSED PROTEIN
`CONCLUSION
`SPECIFICITY INTENSITY .TTARGETSTATUS‘
`
`112
`
`NEGATIVE
`HERZTNEU
`_
`NEGATIVE
`ER
`"N‘E‘G‘AT‘N,—"“_E‘—“' “" —“—'”‘“
`RR'
`POSITIVE
`SPECIFIC_2
`'
`00
`'
`TARGET
`C-KTT
`NEGATIVE
`‘
`EGFR
`00x2—~ NEGATTV‘E‘" _‘
`
`'
`
`'
`
`'
`
`.
`
`1
`
`'
`
`
`
`‘
`-
`0052
`NEGATIVE
`-
`'
`‘
`
`PDGFR
`NEGATIVE
`RNSPECIFIC
`~ CD25
`NEGATIVE
`,
`
`
`
`
`108 .
`'
`110
`'
`* 2+ IHC IN GREATER THAN 30% OF THE TUNOR CELLS HAS BEEN CHOSEN AS A CONSERVATIVE DIVIDING
`POINT TO REPORTA POTENTIAL TARGETAS POSITIYE TO HELP INCREASE PHARMACOLOGIC EFFECTIVENESS.
`
`114
`
`IINIUNOHISTOCHENICALTESTRIDTPERFORMED
`
`'
`
`.
`| LA 2
`TIT-KAPPA BETA
`THYMIDYLATE SYNTHASE
`ERCCIT (HELICASE)
`THYMIOINE PHOSPHORYLASE
`NGF
`NTAP
`NAP KI NA'SE PROTEIN
`XANTHINEOXIDASE
`
`TOPOISONIERASEI
`TOPOISOMERASEII
`.RETINOIC ACID RECEPTOR
`R X R
`ORNITHINE DECARDOXYLASE
`SDMATOSTATIN
`RASIMUTATED)
`ASPARAGINE SYNTHETASE
`
`NLI-IT
`NSH2
`CD20
`P53
`CYCLIN DI
`BCL-2
`VEGF
`
`FIG.3I3
`
`

`

`'
`
`.
`
`PATIENTINEORNATION
`
`.
`
`PHYSICIAN INFORMATIN
`
`-
`
`*
`
`
`
`
`
`
`SOME DOCTOR, NIT
`NAME: SAMPLE PATIENT
`
`
`SEX: FEMALE
`MOLECULAR
`I234 E. SOUTH ST.
`‘
`
`
`
`DUB: (gm/1974
`.
`_
`4 TUCSON,AX 12345
`
`
`PROFILING
`¥ SSNII: 123-455-6789
`, 480-123-4567
`
`
`
`
`INSTITUTE
`
`
`
`VER1.6.2:4-2‘5-08
`REPORT INFORMATION
`7
`
`DATE SPECIMEN RECEIVED: IIEIIIIIzooE DATE REPORTED: 02I09I2006 CASE NO. IIPTNoe-NIN
`
`
`1 DATE SPECIMEN COLLECTEDAT HOST MEDICAL CENTER: 01I24l2006
`
`
`
`
`
`
`
`
`
`
`I
`
`'
`
`
`
`
`
`
`
`
`
`
`
`
`'
`
`'
`
`.
`
`
`
`
`
`~
`
`
`
`
`
`
`
`
`
`SPECIAL STUDIES
`MICROAEWIEYRULTS
`18
`
`
`'
`..
`V
`.
`I
`
`m
`18
`r100
`16IIIICROAREAYANALYSIS:118 16
`
`
`
`
`
`
`
`
`,GENE
`RATIO EXPRESSION ANALYSIS
`GENE
`RATIO EXPRESSION‘ANALYSIS
`
`
`
`
`
`II-UNEEEEXPRESSED EGFR III' IIII .
`
`
`0.09II IIII- II
`ESE
`
`III- MLHI III III-
`-_- --- ZAPTE
`306 N0 CHANGE -
`
`
`
`
`III- IIILI
`INI-
`IIII IIII 3.16—-
`
`
`
`
`UNDEE EXPRESSEDI III I EVEREXPRESED I
`
`
`
`
`
`IIII III OVEREXPRESSED I.
`II I OVER EXPRESSED - I OVEREXPRESSED I.
`
`
`
`II III- II
`
`III- III HIFIA
`OVEREIIPRESSED I‘
`
`PDGFRB-_.- III III
`
`
`
`
`
`
`0.80II BECAZ III II
`sou
`
`ESTPI' II GARE III—I III
`
`
`
`
`SPARE II IIOI‘EREXPRESSED I HIFIA VII
`
`
`
`
`II III IFIA II
`
`
`III POINT .0I‘ERBIPRES‘SED I III-
`
`
`III III FDGERA-_-
`III III- II
`
`
`
`
`
`SSTRI II II ABA 5.26—-
`
`II III TOP2A III
`
`
`
`
`
`
`
`
`TYNS O-EREXPRESS D I
`III-
`I“NO CHANGE" INDICATES THAT THERE IS NO DIFFERENCE IN EXPRESSION FOR THIS GENE BEIIEENTHE TUMOR AND CONTROL
`TISSUES ATA SIGNIFICANCE LEVEL OF P<=ODOI A SIGNIFICANCE LEVEL OF P<EDDOI HAS BEEN CHOSEN SINCE GENES PASSING .
`THIS THRESHOLD CAN BE VALIDATED AS DIFFERENTIALLY EXPRESSED BY ALTERNATIVE METHODS APPROXIMATELYSS'N OF THETINE.
`
`

`

`PATIENT: SAMPLE PATIENT
`
`CASE NO. MP~TNOS-O5OAO
`
`‘I 0.0
`
`fl
`DATE REPORTED: DEMONS
`
` ' CLINICALINFORMATION
`' CLINICAL HISTORY
`
`N THEPATIENTWASDIACNOSEDWITHIRELANDORYMYOFISROBLASTICTUMORINFEB2004.ATTHATTIMEALARGE
`
`MASS WASREMOVED FROMHERABDOMEN THE PATIENT NOWHAS RECURRENT MASSES ON HER LEFT UPPER OUADRANT
`AND IN THEPELVIS. PERTHE PATIENT CHART DR SOME REVIEVED THISCASE WII H DR VON HOFF AND IT WAS AGREED
`THAT PERFORMING DNAMICROARRAYAND IHC TESTING ON THIS PATIENT MAY PROVIDE INSIGHT INTO FURTHER TREATMENT
`
`1 20
`’
`
`OPTIONS.
`
`SPECIMENSSUBMITTEO
`RECEIVED FROM MAIN HOSPITAL, TUCSON, A2,, ONE PARAFEIN BLOCK LABELED 1101-123 AND FROZEN TISSUE WITHTHE
`ACCOMPANYING SURGICAL-PATHOLOGY REPORT.
`
`122
`
`DISCLAIMER
`THESE TESTS WERE DEVELOPED BY MOLECULAR PROFILING AND THEIR PERFORMANCE CHARACTERISTICS DETERMINED
`BY MOLECULAR PROFILING IT HAS NOT BEEN CLEANED OR APPROVED BY THE DS FOOD AND DRUG ADMINISTRATION
`FDAgTHESETESTSARE PERMITTED FORCLINICAL PURPOSES AND SHOULD NOT BE REGARDEOAS PURELY
`VE TTGATIONAL OR FOR RESEARCH. MOLECULAR PROFILINC IS CERTIFIED UNDER THE CLINICAL LABORATORY
`IMPROVEMENT AMENDMENTS OFI SSS (CLIA) AS QUALIFIED TO PERFORM HIGHCOMPLEXTTY CLINICAL TESTING.
`DECISIONS REGARDING CAREAND TREATMENT SHOULD NOT BE BASED ON A SINGLE TEST SUCH AS THIS TEST RATHER
`DECISIONS ON CARE AND TREATMENT SHOULD BE BASED ON THE INDEPENDENT MEDICAL JUDGMENT OF THE TREATING
`PHYSICIAN TAKING INTO CONSIDERATION ALL AVAILABLE INFORMATION CONCERNING THE PATIENTS CONDITION
`INCLUDINC OTHER LABORATORYTESTS IN ACCORDANCE WITH THE STANDARD OF CARE IN A GIVEN COMMUNITY
`THE FINDING OF ATARGET DOES NOT NECESSARILY INDICATE PHARMACOLOGIC EFFECTIVENESS.
`
` 4...,
`
`
`ETA/2006
`7
`:
`ROBERT J; PENNY, NDPATHLOGISTAND NEDICALDIRECTOR DATE
`
`FIG.3D
`
`

`

`com
`
`mom,
`
`wow
`
`mom.
`
`
`
`mSDQEOE<>n_:.zmo_
`
`25024.10<wtmfxwZIP56mg
`zofiwmmmxm
`
`n5>._..._<m:._n_<z_
`
`
`
`wish—$52.mmmdmma
`
`03mm<mmkm_z_§o<
`
`m1...OHEdam;
`
`
`9259203amw<mm5
`
`mIH:mfxm.35
`
`szwmmaxmz_mozafo
`
`>z<mzfimmflo
`
`mE.z.mmOz<Io
`
`
`
`501$.$320505
`
`mommmfim2—Qm_..=._.zmo_
`
`v.9“.
`
`
`
`

`

`
`
`EEmVrmEOmasw2928945230
`
`
`
`
`
`
`
`Ema/Coma03mm
`
`
`
`
`
`mz_o_mm_§DmNfi<zowmmmawwdméQEfimOmZ
`
`
`
`
`
`mozzonfioo63mmw>m4mwzhO._.mwzoammm”mo_._.m_mm5¢m¢xuwmmakfimammm<me
`
`
`
`
`
`
`
`
`
`
`
`.szEQE<$350“<8
`
`
`
`
`
`..m2_ozwE8._83mREE..oz_z_2a_m>._<z<V
`
`Ezogm:
`
`mzazm
`
`
`
`..Qmmaoxmm<§<g..
`
`EEEE@3233....,.
`
`‘.mm_m<zo__55
`
`
`
`QUE
`
`5.2%
`
`
`
`
`
`.750.5025.
`
` mag$028
`
`Iomfimmm52:0
`
`
`
`
`
`
`
`
`
`
`
`
`
`«So7,\flmmfifi@2225\wngme,Vwings“:43%50
`HV20%th§..
`
`H.38memg:ENE.9ng
`
`
`
`
`
`
`
`
`

`

`EEEEEOEE
`
`ZQEEEZEEEEEEEEEEEGEEEm;.
`,_EEEQEEE
`
`.325%mm;
`
`25%Egg2220mm322:0
`
`Ema/0mm
`
`
`
`
`
`wo<l0._n._.2>Ez,m«EEOomfifiu.-mmg
`
`
`
`$2,mag?
`
`.E23“523%>E2wBEES
`
`SE353%32.48%?$23sz.
`
`<_>mafiaE52;EEESE.
`
`5%3
`EEEEEEEEEEE
`.EEEEEEZE.
`_EEEE.
`
`EEEEZEEE.
`
`lEggs.:_
`
`EEEEEEZEEEE
`
`455$:
`
`
`
`
`
`.2,EEE,BEE/mamman—EmH.wnwwioé8
`
`5.2%
`
`“Es/$2058252mm;.
`
`ambEEEZEEDEgg
`
`
`
`
`INTEGRATED
`TE VIEWS
`
`.EaEEEEEEE
`
`
`
`H.EEOEEEE_E_EEEEngEEEEEE
`
`INTEGRATED HISTORY
`ORIENTED VIEWS
`
`©.®_n_
`
`BEDS”.ma$580225.48%;
`
`2,2QZEEmagma2.9228.
`
`«g20owmdaaflfimo$2$52SE.
`QEEWgm..om:51%.Lo$55
`
`
`wiseEa
`
`
`
`
`
`megammqméa$9sz52:828
`
`=2; " ammwixawwa
`ISIIVIS
`I
`STOOL 1V3.
`' ONISSEIGOIId 30W“ I
`SOIWOHIO‘dd
`‘
`SOIINONEIE)
`
`ISTRIBUTED
`SUJECT ORI
`
`
`TomfizmmmxlwmBEBEqumason:.EaSQwEg
`92BE8,62%asécmm_(Ea.5%«EV.
`
`«Ea5&8lo02a?«E.Ea
`
`.mwzozééEEG.,SEEa3$8:me
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`

`N .
`
`OE
`
`r..._——__————.—4—...._~_u-u—-—-—
`
`29222222222
`
`22222222022Em.
`
`
`
`2222222(2222.522.
`
`222222222.20.
`
`
`2222222220.
`
`.
`
`222222222
`
`
`
`2.228222%;:22
`
`
`
`.2223cm:22222222222:
`
`
`2222222222222.2222222222822
`
`22222222_
`
`825%mm;
`
`
`
`
`
`Ewpwxrwhmonaawz.Q_m_owm_._<o_2:o.{sifinnunuuuunnnnuuuuunnnuun..§_{.
`
`
`
`
`202228222222222:.222223222...22222222222222.
`
`22222298.:222222222222222222222222.
`2222.222..
`
`.¥22222222222222.2222...2__222222222222
`
`
`
`
`
`
`22.222.“22.22.22222......22.222.222.22
`
`
`222222.mafia.222228.
`
`222mm22.,,.22282222;
`
`22222.22222.,_..2222222222
`
`
`,22222222222202222W22w2m.
`
`22.2
`
`
`
`
`
`
`
`
`
`
`
`
`
`222222222222222222222..22222222222..q,2222222222...2222222222
`
`
`
`
`
`22%,_.2220.
`
`
`
`”5&2599222222.23.2.58:
`
`
`
`
`
`
`
`22m.,..._
`
`.282820..
`
`mmfima02.mzme
`
`wagofiz$
`
`222.2222
`
`22222202222
`2222222222
`
`2223222222
`
`
`
`
`
`22222202222222:.2222+22w2wmmm82
`2222288.,,_‘
`
`
`
`29.225222.22m2zoo.
`
`
`
`225222222222.222.222222222222222...
`
`
`
`.222222222.2..222222222,2.202222
`
`
`
`
`
`222222222222.,..222222
`
`2222202222..22222222.222222.22
`,,
`
`
`
`.2222222
`
`
`
`
`
`
`
`
`
`
`

`

`><mm<omo§.
`
`QZEEOZmG.
`
`wQEOmHomm.
`
`
`
`.Emmzooamid.
`
`
`
`35kmHzm2m0<wz<§w0265.4535:8;me
`
`huggmf.
`
`OI...
`
`-59mm53015.,
`
`Mao.
`
`
`
`
`
`“Em,__.27:.
`
`EmfiiK..
`
`FzmzamK
`
`
`
`
`
`
`
`

`

`
`
`
`
`
`
`QOE
`
`28988
`
`$2243
`
`>53;.
`
`.2.5m.
`
`(22553}:
`
`.Ema6%
`
`,WEE?
`(50:28
`
`
`
`
`
`‘
`
`3%?me
`€me
`
`
`
`$85.33:.
`
`Emzézggem.
`
`295.5%
`
`,
`
`3;?
`
`..$0ngEa
`
`Egg
`
`E5329sz50:
`
` 20.,5m2mw5
`
`
`
`
`
`mafia,$me,42a,_<5
`
`
`Emagzggem22%Egfimgroggy,..Eggmgmfimfig
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`

`
`
`mmNBmgzfim._<u._z_._u
`
`>m<._:m<oo>
`
`V
`
`_
`
`
`
`
`
`.mz<_u_m>In_..<z<_o_m>Im
`
`,MmmrxEmfii
`
`“$.5me
`
`
`
`wagewas)It;88225E?
`
`”ngE/Ewmo
`
`mmSAFzmfii
`
`.szmm
`
`833%M.88582%
`
`
`
`zmjkmm
`
`$8582%
`
`033%
`
`,.
`
`,
`
`mo292:0.
`
`
`
`
`
`magma.ooogmsm3:55
`
`.nur.mmv_.”&
`
`
`
`
`
`
`
`

`

`
`
`
`
`mmm<mggézmwxm
`
`EQIOE
`
`mm>mmm.
`
`”magma.,
`
`EmaE.
`
`finnefifinfl
`
`c
`
`mm<m<._.<o
`
`z.o_.m.<Nj<:m.>\m5§<z<nEmpmfim
`
`
`mmEEgot—n5.
`
`«Ema..,\Iw
`
`g
`
`
`
`.295248
`
`EEEHEE
`
`.
`
`
`
`>331;$5me
`
`$.95.28gig.
`
`
`
`age.55%:
`
`_,.smugmméfié
`
`
`zoammemwzmoEmémgs.
`
`50%$5sz\f
`
`29
`
`(K?5.9
`
`
`
`
`
`
`
`
`
`

`

`Mill
`
`|
`
`ll“: ,
`
`lllll
`.
`“I1;
`"in.
`
`
`
`mmjozmmfisfigEa:
`
`m._.<>_m&o:m:m
`
`mm<mdm
`
`mega
`
`$5E05$5V
`
`‘$.40
`
`w_m>.Ez,q
`
`m._oo._.
`
`.
`
`
`
`
`
`zmwmmflvm..E3Egg
`
`mmzzgm
`
`
`
`>53%..
`
`37E._§z_.._o
`
`392:0
`
`ma
`
`._.zmfi<n_
`
`mo
`
`
`
`
`
`
`
`

`

`ESE
`
`
`
`@253,...._.,.magma”gig
`o.a:m2%203%onoo.
`
`$53
`
`
`
`,.._,_o_zwmmwo¢.,;.
`
`
`,205%?292.3%
`
`Eofigm
`
`
`
`
`”$53ng222323......
`$22228mam
`20.53$2.925»Essa
`
`
`
`
`£20925%585%awwémmg
`
`$8ngm3“.E
`
`$2,
`
`$938
`
`Hmggmm
`
`
`
`$23:2
`
`£2,123
`
`_._5_z_.5$§<w
`..2Gigi
`
`$23SEE;
`
`._,558,350%,
`
`gags
`
`5.85:5
`
`
`223222222222222“22.20222.,”m2222
`§§$33,2222
`
`
`..222222222222
`
`
`
`
`
`mmsg
`
`EEK
`
`
`
`
`
`
`
`
`
`
`

`

`
`.._,.Cwmmzo_t._.o<ma
` s
`
` ,.mmngtho/Em,mumI.EUEw—z
`
`Ezmfifiw._.zm:<n_
`
`
`imam—2
`
`
`
`magmaI
`
`,
`
`" PR MPI
`HRS,Mm
`E
`_WPWON
`
`‘
`
`DIAGNOSIS,
`
`PROGNOSI‘
`I
`TREATMEN
`
`DIAGNOSIS -
`PROGNOSIS
`* TREATMNT »
`
`omw<m.zo_._.<§m0mz_n6meSEZ
`
`
`
`
`
`mz.,o_om§mej<20wmmn__
`
`
`
`
`
`

`

`EEEEEEI,
`
`.EEEEEEEEEEEEEEEESBEEQEEEEEEEEEEEEE
`
`
`EEEEEE.EEEEEEEEEEEEOZEEEEOEE
`
`EE
`
`EEEE
`
`EEEEEEEEEE
`EEEEEEEEEEEE
`
`EEEEE
`
`
`
`E228EEEEEO.
`
`EEEEE
`
`EEE
`
`EEEEE
`
`EEE,.,
`
`EEEEEEEEEEEEE
`
`EEEEOEEEE
`
`EEEEEEESEEEEEQNEEEEEEEEENEEEEEEEEEEO
`292N256
`
`
`
`
`
`IEEEEEEEEEEEEEEEEEE
`
`IEEEEEEEEEEEEEEE__EEEEEEEEEEE
`
`EE.EEEEEEEEEEEEEEZEEEEéEEEEmEEEEEE.o
`
`EEEEEEEEEEEE
`
`IEEEEEEEEEEEEE
`IEEEEEEEEEEEEEEEE
`
`EEEEEEEEEEEE
`
`NEHEEZE
`
`IEEEEEEEEEE,
`,..EEEEEEEEEEEEEEEEEEEEE.
`
`
`
`
`
`EEEEEEEEEE
`EEEEEEEEEEE
`
`EEEEEEEEEEE
`
`EEEEEEEEEEEE
`
`EEEEEEEEEEEEE
`
`
`
`EEMEEEEEEEELWEEEOE
`
`
`
`EEEEEEEEOEEEEEEEEEEEEWEE.MEEEEEMEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE
`
`
`
`
`
`
`
`
`
`
`
`

`

`IIIIIIIIIIIIIIIIIII
`
`
`
` IIIIaIIIIIIIIIMNIIIIIII.IIIIIIIIIIIIIIIIIIIIIEEIBZI
`
`
`_EII.nIIIIIII.._mIIIIIIIIIIIImIIIEIIIIIIIIIIIII.
`
`
`
`IIIIIIIII.IIIIIIIIIIIIIIIIIOzIIInIomnI
`
`
`..IIIIIIIIIIIIIIII
`
`
`HHIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIEIIIII
`HmIIIIIIIIIIIIIIIII|IIIZII$561538
`
`
`IIIIIIHHHHIIIIII.IIIIIIIIIIIIIIIIIHIIIIIIIIII
`
`
`
`HHHIIINIIIIIIIIIIIIIIIII
`
`HUIIIIIIIIIIIIIIIIIIIII
`HUIIIIIIIIIIIIIIIIIIII
`
`
`Isa?IIIIIIIIIIIIIIIIIIIIUIIIIIIIIIIIIIIIIIIIII
`
`
`HHIIIIIIzIIIIIIIIIIIIII
`
`
`HIIIIIIIIIIIIIIIIIIII
`
`
`
`
`
`IIIIIIIIIIIIIIII.IIIIIII
`
`IIIIIIIIIIIIIIIIIIIIIIIII
`
`IIIIIEIIIIIIIIIIIIIII
`
`BQ@9%“aE.EE.
`
`$32865.
`
`
`
`,
`
`III
`
`
`
`
`
`
`Hill!.3IIIIIIIIIIIIIIIIIIIIIIIIIIIIII
`
`.IIIIIIIIII
`...anI
`
`

`

`HUMVaEEEnoHE553ch
`
`2%
`
`Hmém$2._.3N5552EWIIHWHIIIUILNHEE“22:.HwHEE:5620835
`
`
`IIIIIHTEQmg,7wwwmmofiwfi
`
`WHHE5.52,Nzogzémo.
`
` gig.
`
`33%.
`
`EdazwfifiaémE5mS._._.~mz_
`
`...__.-If__..H_w02_.=u_omm
`.42”,35:3..
`
`
`
`.es2gm?2:52&5$53050:
`
`
`
`BQMy9am“aEmIha:gag.”$.QO$98ng£7:E):9.a:I
`
`
`
`:mama”QLMIm8
`
`
`
`
`
`

`

`.HHHHHHHHHHH-
`
`
`.H|._HH..HHH.HH..,.IHHHHHH
`
`....lHHHHHHH
`
`.
`
`
`
`
`IHHHHHHHHHHHHHHHHHHHHHHHHH....HHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
`
`
`lHHHHHHHHHHHHIHHHHHHHHHIHHHHHHHHHHHHHH
`
`HHHHHHHHHHEHHHHHHHHH.,
`
`..,HHHHHHHHHHHHHHHH
`
`
`
`.HHHHHHHHHHHHHHHHH.HHHHHH
`
`
`.HHHHHHHHHHHHHH..
`
`
`_|HHHH.EH.HuHHHHHHH
`
`_IHHHHHHEHHH.HHHHHH
`
`
`
`HHHHHHHHHHHH
`
`HHHHHHHHHHHHHHHHHa..:
`
`HHHHHHHHHHHHHHHH_.....H.HHHHI...
`
`....HH.H.HHHHHHH_HHHHHHHHHHHH
`
`
`
`HHHHHOOHHHHEHHQHHHHHHHHHo.HHHHHHHac.9332HHHHHBHHH.HHHHHHH
`
`
`
`HHHHHHHHHHHOoHHHHHHHHH@.HHHHHHHHHOHHHzHHHHH.HH
`
`HaHHHHHH
`
`
`
`HHHHHHHHHHHHIHHHH
`
`HmEHHEHHHEHH—
`
`HH3%HHHIHQH
`
`
`HHBHHHHQHHHHHEH
`HHSHHHHHHHHHH
`
`
`
`
`
`
`
`1%....@flEDP—52.wzzmommmisomHOEB@99%.@
`
`
`
`.HHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHH
`
`
`
`
`
`
`
`
`
`
`
`

`

`mwgéfig..0%E453?
`
`
`@@@9%.@,wwfi3mg3...
`
`
`1m:3225..ExamwmmoaxgmaE2E}:3WEa.
`
`E.§E
`
`
`
`mwozm6901:;we55m
`
`.._zo_.Emm&Ez_
`
`
`
`E228yafimgfiz
`
`Zecémonszfizzu
`
`,.
`
`
`
`;.$9935.25
`
`
`
`‘.7.3:_2m3mmzw§am¢m
`
`
`
`Juneau?
`
`

`

`
`gi
`
`MICROARRAYANALYSIS
`"
`RRRIRRHRRRRRRRRRRRR R-iImRRRTRRRIRRR RRRIRRRRRRRRRRRRRRRR
`,
`RRRTIRRRRRRRTRRR- RRTIIRRIRRRI- IRRIIIRIRIRRRRI-
`5%AK
`WT -[RRIRRRRI-
`RRRR I TUTTI-GENES 71
`2C:- C.)at:Emm
`g93
`MNROTfigITIRTRI-IIIIII
`.
`.
`EQ?“
`-RRIR- RRRIRRI R
`;~13E::E3?I
`IRRIIRRIRRRRI- TlgTTTIIITTIIIDII
`2:TO
`RRR l---1
`Q
`IRRRRRRRRRR- IRRIRIR
`:1-
`g
`MRRRRRRR-
`aE EE;i E
`RRIIRRRRR RR-
`03Amt-11
`I-IRII,
`I.
`-
`’m."% x—yc)“-c:73:31.11.LlIIII<11:
`II
`g%4%.
`._L.
`FF.
`m c;"—35%x,F0mr‘fi‘
`.asmm1—K:
`I'-.im%‘ml‘fi
`
`z%o%.
`‘1-%
`g:. H 4
`E4 I
`
`
`
`5'!
`
`C:
`[TITS]
`BET
`
`[MT
`
`
`
`"=1%STEa:.53.‘
`
`.
`
`(5‘3
`
`a
`
`
`
`E5—?
`I-
`
`-
`3%
`
`E
`
`éIn E:E:
`
`4!:~81 i §:s%%:~r-—130*Iggl
`2-zo6:}: C'}~=2:.42-—
`G)(I)mm
`2>m «I
`ZZZOco.("an2529-(7.,cwfi'f“r—ru
`rruw—u
`.fl.5‘
`gar-I
`xv»?-A“
`
`.4
`
`...I
`
`EE
`
`
`
`4-—E
`
`E
`E’s“
`
`.
`-
`_,
`-
`'
`IETTIITOIIIIITIIIRIRI{MRIIITIIIIRT‘ITRTTWAIMITRI'
`Em?dEEEI-IIIIIIIIIIIIIIII
`I'RIRRIRRRRIR—
`.
`II
`4 123E NORTH ST
`MOLECULAR SETS
`FARGO 111312345
`v
`R4
`333453-7890
`v PROFIUNG SDTI': ImIiTR
`INSTITUTE 1DATESPEDIMEN RECEIVED.
`CASENO.TITPTITTOSIB
`DATE REPORTED.
`.
`DATE SPECIMEN COLLECTEDAT HOST MEDICALOCENTER;
`
`PAGE SOFT
`
`4
`
`E fi
`
`-7»%NT%61’.
`
`g
`
`..OI-Q1%
`
`.
`
`:14g
`
`
`1:3%%‘33.
`
`,i E§§§%§§%%%§§:$
`
`
`
`.(‘32:?)
`
`a
`
`:0Do
`
`‘n5%*:age:
`
`'
`‘
`
`“ROOT-TAHOE INDICATESTHATTHERE ISNODTFFERENCEINEXPRESSIONFORTHSGENEBETWEEN
`THE TUMOR AND OONTRDLTISSUES ATA SIGNIFICANCE LEVELOF P<=0.DOT. ASIGNIFICANCE LEVEL
`OF P<=DTID1 HAS BEEN CHOSEN SINCE GENES PASSINGTHIS THRESHOLD CAN BE VALIDATED AS
`DIFFEuITENTIALLYPRESSEDBYALTERNATIVEMETHODSAPPROXIMATELY9.5%OF'THETIME
`
`FIG.20
`
`

`

`
`
`
`4444444444444444444...I._444444444444444444444402440444
`
`44,4.4444444II4444444:
`
`.44444444445444.4444:444444444444454.452.
`
`
`
`
`444,4449%44ENE@fl
`
`
`
`444444.44444444444444440444444
`
`44444444@444.44444444444444444444.§
`
`
`
`444424404444
`
`
`
`4444444444.444444444444444
`
`
`
`4404444444444444
`
`
`
`44544442.444
`
`
`
`4444.54.44440444444444,
`
`022044444
`
`4444444444..
`
`4444444444444
`
`4444444444444444444..
`,
`444444444
`
`
`
`.444444444
`
`4.4444444444442444
`
`mflU44444444444
`
`
`
`mflu44444444444
`
`DU44444444444
`
`ufl444444444444
`H44444444444444
`
`IU4444444444444_
`
`uflU444444444
`uflu444444444444
`
`
`EMU4444444444444444444444U4444444444
`
`
`
`EMU4444444444444444444
`
`
`umHu4444444444444444444444444444444
`
`flu4444444444444444
`4444444444
`
`NU4444444444.V.4444
`
`
`NH444444444444444444444444
`
`
`
`
`444444444444444444444
`
`4444444444444444444
`
`I11111!...th
`
`4444:444mdza444444
`
`
`
`4444444444. V
`
`
`
`
`
`
`
`444444.4444434444444
`
`.44444444444444
`
`20.444444444424494.
`
`4444444444444444444.444
`
`44444444444444
`
`44444444444444
`
`m4444444444544.
`44444444444444
`
`
`
`
`
`
`
`
`
`
`
`444444444444444.444444844444444444.44444444.:4.4.4-
`
`
`
`
`
`
`
`
`
`
`

`

`
`
`
`
`mozmomx38%?.$582
`
`
`
`$8.,582
`
`
`
`Ed.:53a
`
`
`
`“2.282
`
`IIIIQBya
`IIm
`V
`IIIIIIEI
`
`mmqmfléa:.0Emmézfimfi
`5335352.A_§V._Egg62%;:va.
`
`
`
`
`
`
`oémmmgxmmzmwEma?—gmfiw.Zggawwmgézmw
`32%:wag5a.53:02.0ENEazaxwiWig
`.”Egg;o$ng.,it‘_
`$3302032%o539%Eggs2;...
`
`
`
`..,.._Eadie?5&3?“go.§g5.8%?2%?$05330;
`Egg?5%a2$32on23%.Em.“HE
`
`
`gugmgééggggagiwafimgga
`ENE..SEmafia,#2ng
`
`
`
`
`@2525“£8.ng2.033
`@2552ggmagwm
`
`3.
`
`.0
`
`‘5
`3|
`
`
`
`$1gggamggmwmmswm25%52E»Ea:a$3me
`
`.nWwEfigau
`.Eggalmg.‘
`
`
`

`

`Hammad;MNOE.,,.,,mafia-mg.
`
`:
`
`
`...,..1,,,
`..
`.HHHHHHHHm;HHHHHHH:I
`
`
`H2220,,H2H3.82H.a:$832%EHWHOHHHHHHHHHHHHHHHHHHEH:m22HmHHammmHquomoEEons:
`
`5%:HgmagwQ5HHHZHZHHHHHHHHHHEHOHHHHHHHOHHHHHEEHHeHHHHHHHHHHHEEa
`
`:HE.HHHHHSHSHHHE
`HHEHHHHHHHHHHHQHHHHWHHHHHEHHH233mfg;..HHHH
`
`
`55HH5%GREG“:OHmgswmmHEHOE.,HHHSHH
`
`EnemiesmafiaHHHHHHHHHHHHOEHHHHEHHE
`
`.HaHI:QHHHHHHOHHHHHHHHHHQHO$22H:aHz2Hm.....HHHHH.H
`HHEHHHHHHHEHEHH20%QHHHOQHHHHEHHHHHHHEm
`
`
`H250:HHHHHHHHEHHHH:HQHHHHHOHHHHHHHHHHHMHHHHQHH.
`HHHH:Hg:HHHHHHQHHHHEHHHHEEH9.5%HQ11:.
`.HHDHHHHHHH32HimOHHHHHQHHHHHHHHHHHHOHHHHH
`
`
`
`ale—N
`
`CiV—‘mV—‘T‘TJWN‘WV—vw
`
`N
`
`
`
`1meon?meHHHHHH”HEm
`
`
`
`HHHHHI‘HHHHHHHZHHH”HHHHHHHHHOHHHHHHHHHQH
`
`
`
`
`
`
`
`
`
`.Hsomm29%Ha.HagmHHHHHmHEEHHE”HEEEHHHmanm
`
`
`
`$23582:meH.H
`
`
`
`
`
`
`
` .2%”302,53525me..
`
`
`
`
`
`

`

`§EEE.EEEEEEEEEEEEE.
`
`EEEE.EEEEWEIEEEEEEEEEEEEEEEEEEEEEEEEEEEEEBEQEE
`
`
`
`
`EEEEEEEEEEEEEEEE.EEEEEEE§023.6%EEEEEEEEE..EuEEEEEEEEDEEEEEEEEEEEEEEEEEEEEEEEEEEE.a,,EEEEEEEEEEEEEEEEEEEEEEE
`
`
`
`
`
`
`..%EEEEwE
`EEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEEE..EEE-V
`
`
`
`.EEEEEEEEEEE
`EEEEEEEEEEEE
`
`EEEEEEEEEEEE
`EEEEEEEE
`
`EEEEEEEEEEEEEEEEEEE
`
`ESEEZE
`
`EE
`
`EEEEEEEE
`EEEEEEEEEEEE_.EEEEEE
`_EEE
`
`EEEEEE
`
`EEE
`
`EEEE
`
`DUEEEEEE39$0;
`
`EmmmumEEOEEEOEEEDE5%vvmEEEEo29m.8ME:v.53.
`
`
`
`
`
`
`
`.
`
`.32%E02
`
`fl.EEEEEE.DEEEE-
`
`EEmmeEEm:EOE
`
`
`
`
`
`
`
`
`
`

`

`
`image mm.CW.—mugingham—g.
`fl.,
`
`3%53%Eggoz_,__u_oma
`5%“E52.
`
`52533,mi.5%”0520.misoflos.
`
`
`
`;m5:$meon
`
`2&5;th$93.8EOE.vw.
`
`
`
`$20552«zwaommmga
`
`
`
`..quomos.
`
`
`
`”Emmmumm><mm<o5§mEmmegaEgg
`
`@9@@.%“amflfim53%fig.
`
`_a:Egg”3%.232EE,Egm"
`
`
`
`.33?“$ng52.ogmwfizgzfi
`
`
`

`

`FIG. 26A
`
`Tumo r Type
`
`Adipose tissue,
`if not available use
`Adrenal Cortex (18)
`fibroblast (1)
`Adipose (13)
`biomarker
`biomarker
`biomarker
`tumor
`flagged as
`flagged as
`flagged as
`type
`target
`target
`target
`_-__—__
`—__—__
`—_—___
`—_—___
`—_—___
`—_—___
`
`—_—___
`—_—___
`—__—__
`—_—___
`
`—__—__
`—_—___
`
`Adrenal Gland (1)
`biomarker
`flagged as
`target
`
`0.00%
`0 00%
`0.00%
`0 00%
`0.00%
`0.00%
`33.33%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0 00%
`33.33%
`0 00%
`0.00%
`33.33%
`0.00%
`0.00%
`
`1
`
`1
`
`1
`
`Adrenal
`Gland —
`Medulla (15)
`biomarker
`flagged as
`target
`
`
`
` W
`
`
`
`Appendix (5)
`biomarker
`flagged as
`target
`
`,_1
`
`1
`
`1
`
`0.00%
`8 33%
`0.00%
`0 00%
`0.00%
`0 00%
`16.67
`0 00%
`0.00%
`33.33%
`0 00%
`0.00%
`25.00%
`0.00%
`0 00%
`0.00%
`8 33%
`0.00%
`8.33%
`0 OO‘V
`
`2.22%
`15.56%
`0.00%
`0 00%
`0.00%
`0 00%
`67.67%
`0 00%
`4.44%
`22.22%
`2 22%
`4.44%
`17.78%
`2.22%
`0 00%
`0.00%
`6 67%
`0.00%
`15.56%
`0 OO‘V
`
`W
`
`,_1
`
`7
`
`Total Number of ICH
`Biomarkers Flagged as
`Taxget for Tumor Type
`Samles
`
`30
`
`100.00%
`
`4
`
`100.00%
`
`56
`
`3
`
`100100%
`
`45
`
`100.00%
`
`12
`
`100.00%
`
`

`

`Bladder (D
`
`Blood Vessel Vain (4)
`
`Bone (2)
`
`Brain (2)
`
`Breast (99)
`
`Cartilage (5)
`
`FIG. 26B
`
`
`
`
`
`Bone if you have it
`if not Cartilage (1)
`# of times
`biomarker
`biomarker
`biomarker
`tumor
`biomarker
`flagged as
`flagged as
`flagged as
`target
`target
`target
`type
`flagged as
`9 81%
`_—___ _
`_—___ 9.26%
`_—___ 0.27% _
`___—___
`___—___
`___—___
`
`
`
`biomarker
`flagged as
`1
`
`19
`
`biomarker
`biomarker
`flagged as
`flagged as
`tumor
`target
`target
`type
`_—
`_—
`_—
`_—
`_—
`_—
`
`_—
`_—
`_—
`_—
`_—
`
`_—
`_—
`_—
`
`_—
`
`_—
`__—
`
`
`
`
`
`___—___
`___—___
`___—m
`___—___
`___—___—
`
`___—___
`___—___
`___—___
`
`___—___
`___—___
`___—___
`100.00%
`2
`100.00% m 100.00%
`100.00% _100.00%
`
`
`
`tumor
`type
`0.00%
`10.53%
`0.00%
`0.00%
`0.00%
`0.00%
`10.53%
`0.00%
`0.00%
`15.79%
`0.00%
`0.00%
`21.05%
`10.53%
`0.00%
`0.00%
`26.32%
`0.00%
`5.26%
`0.00%
`
`

`

`FIG. 26C
`
`
`
`Dendritic cells can be
`found in skin, the spleen,
`lymph node. Let’s get
`Mike Bittner’s take on site Difficult origin to define.
`of origin (1)
`Try skeletal muscle (1)
`# of times
`biomarker
`biomarker
`'
`flagged as
`flagged as
`target
`target
`
`Colon Sigmoid (1)
`# of times
`biomarker
`flagged as
`target
`
`Endometrium (3)
`# of times
`biomarker
`'
`flagged as
`
`Esophagus
`biomarker
`flagged as
`
`Colon (6D
`biomarker
`flagged as
`target
`1
`32
`
`1 1
`
`38
`
`
`
`Cervix (10)
`
`tumor
`type
`0.00%
`9.38%
`3.13%
`0.00%
`0.00%
`0.00%
`12.50%
`0.00%
`6.25%
`21.88%
`3.13%
`3.13%
`6.25%
`6.25%
`0.00%
`0.00%
`6.25%
`0.00%
`21.88%
`0.00%
`100.00%
`
`
`
`biomarker
`flagged as
`target
`
`31
`
`4;
`
`NNr—‘r—‘QN
`
`32
`
`
`
`1——————————
`5 ——————————
`40 ——————————
`——————————
`3 ——————————
`26 ——————————
`2 ——————————
`3 ——————————
`——————————
`20 ——————————
`——————————
`39 —————————-_
`——————————
`100.00%
`100.00%
`100.00%
`100.00% n 100.00%
`
`212
`
`

`

`FIG. 26D
`
`Kidney (14)
`biomarker
`flagged as
`target
`
`tumor
`type
`
`Larynx (3)
`biomarker
`flaggedas
`target
`
`type
`
`Liver (1)
`biomarker
`flagged as
`target
`
`tumor
`type
`
`Lung (74)
`
`biomark
`
`type
`
`Gallbladder (5)
`Fibroblast (D
`Fallopian Tube (3)
`biomarker
`% in
`biomarker
`biomarker
`% in
`% in
`flagged as
`tumor
`flagged as
`flagged as
`tumor
`tumor
`target
`type
`target
`target
`type
`type
`———
`——-
`——-
`——-
`000%- 0.00%
`0.00%_ 0.00%
`11.11%_ 6.25%
`0.00%_ 0.00%
`0.00%_ 0.00%
`11.11%_ 12.50%
`0.00%_ 0.00%
`11.11%_ 0.00%
`
`S (9)
`% in
`tumor
`type
`0 00%
`0.00%
`0.00%
`0 00%
`
`0.00%
`0 00%
`21.43%
`0 00%
`10.71%
`17.86%
`0 00%
`0.00%
`3 57%
`0.00%
`0 00%
`0.00%
`17.86%
`0 00%
`28.57%
`0 00%
`100.00%
`
`1
`
`1
`
`1
`
`--—
`--—
`000%- 0.00%
`__—
`29.41%_ 30.95%
`3
`__—
`__—
`17.65%_ 16.67%
`3
`
`5.88%
`
`2.38%
`
`1
`
`5
`
`1
`3
`
`1
`
`Lymph Node (9)
`% in
`tumor
`biomarker
`type
`flagged as
`0.00%
`0.00%
`27.27%
`%
`
`2 6
`
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`22.73%
`0.00%
`4.55%
`9.09%
`0.00%
`0.00%
`0.00%
`4.55%
`0.00%
`22.73%
`0.00%
`100.00%
`
`5 12
`
`1 5
`
`22
`
`0.00%
`
`0.00%
`
`1.79%
`
`_—__
`25.00%
`0.00%_ 24.55%
`_—__
`
`0.00%_ 13.39%
`1.3
`0.00%
`4%_
`
`34
`
`28
`
`52
`
`0 00%
`
`25.00%
`8.33%
`
`8.33%
`
`
`__—
`0.00%_ 0.00%
`
`
`
`
`__—
`__—
`“-
`—_—_—_—__-I
`0.00%_ 0.00%
`__—
`_—__
`—_—_—_—___
`_—__
`
`

`

`FIG. 26E
`
`(40) W as)
`
`a)
`
`Prostate
`(a
`
`tumor
`flagged as
`tumor
`flagged as
`tumor
`flagged as
`tumor
`flagged as
`tumor
`flagged as
`tumor
`flagged as
`tumor
`flagged as
`type
`target
`type
`target
`type
`target
`type
`target
`type
`target
`type
`target
`type
`target
`____—_——___ 5
`“_____———_-_ 2
`_____—_——__
`____———____
`____———____
`____———____
`______—_——_ 3
`_____—_——__
`____—_——___ 1
`mm 4
`_____———___
`mm 1
`mm 4
`——————————-
`_____—_——__
`____———____
`8.70%
`14
`
`biomarker
`
`%in
`
`biomarker
`
`%in
`
`biomarker
`
`%in
`
`biomarker
`
`%in
`
`biomarker
`
`
`
`biomarker
`
`
`
`
`
`biomarker - biomarker
`
`flagged as
`target
`
`3
`
`25
`
`____———____
`mm 2
`____———____
`
`
`
`

`

`FIG. 26F
`
`(6)
`
`Salivary Gland (5)
`
`Sinus tissue (1)
`
`Skeletal Muscles (2)
`
`Small Intestine (4)
`
`smooth muscle (3)
`
`Smooth Muscle such
`as smooth muscle from
`the intestine Without
`the epithelium, ditto
`for the uterus
`ie no endometrium (1)
`# of times
`biomarker
`flagged as
`
`_____
`
`
`biomarker
`biomarker
`flagged as
`biomarker
`flagged as
`target
`flagged as
`target
`___—
`___—
`___—
`___—
`___—
`___—
`___—
`___—
`___—
`
`tumor
`type
`20.00%
`8 00%
`0.00%
`0 00%
`0.00%
`0 00%
`12.00%
`0.00%
`4 00%%
`16.00%
`0 00%
`4.00%
`16.00%
`0.00%
`0 00%
`0.00%
`12.00%
`0 00%
`8.00%
`0 00%
`100.00%
`
`0.00%
`20.00%
`0.00%
`0 00%
`0.00%
`0 00%
`20.00%
`0.00%
`0 00%
`20.00%
`0 00%
`0.00%
`20.00%
`0.00%
`0 00%
`0.00%
`20.00%
`0 00%
`0.00%
`0 00%
`100.00%
`
`5
`
`tumor
`type
`
`___—
`___—
`
`___—
`___—
`___—
`
`.0
`
`_27.27%
`_____
`_____
`_____
`_____
`_____
`_____
`_____
`_____
`_____
`
`___—
`
`_____
`_____
`
`___—
`“__-
`
`

`

`FIG. 26G
`
`Stomach (6)
`
`Synovium (1)
`
`Tendon (1)
`
`Testis (1)
`
`Thymus (2)
`
`Smooth muscle such as
`Uterine wall but not
`uterine lining i.e., not
`endometrium (1)
`# of times
`biomarker
`flagged as
`
`biomarker
`flagged as
`
`biomarker
`flagged as
`target
`
`biomarker
`flagged as
`target
`
`Synovium or
`joint lining tissue (1)
`# of times
`biomarker
`flagged as
`target
`
`
`
`
`
`
`
`
`
`
`20.00%
`0.00%
`20.00%
`
`1
`4
`1
`
`5.88%
`23.53%
`5.88%
`
`1
`
`0.00%
`20.00%
`0.00%
`
`0.00%
`0.00%
`0.00%
`
`
`
`5 100.00%—
`
`100.00%
`
`100.00%
`
`100.00%
`
`tumor
`type
`40.00%
`0 00%
`0.00%
`0 00%
`0.00%
`0.00%
`40.00%
`0.00%
`0 00%
`20.00%
`0.00%
`0 00%
`0.00%
`0 00%
`0.00%
`0 00%
`0.00%
`0.00%
`0 00%
`0.00%
`100.00%
`
`

`

`FIG. 26H
`
`
`Overall
`
`Thyroid (4)
`Uterus (3)
`Uteruszcorpus (10)
`biomarker
`
`flagged as
`_______78_4.5%
`________—
`_______—_
`————————-
`________—
`_______-_-_
`_______—-_
`mm.
`mm
`mm
`_______—_
`________—
`________—
`
`_______—_
`________—
`
`
`
`
`
`
`
`
`
`_____—__-_
`__0.00%_1_12.50%“—17.78%_224
`_______-_ To-oisomerase II al-ha
`m "in—__—
`_ _____
`_ _—_—-_
`
`
`
`
`
`
`
`
`

`

`Adipose (13)
`# of times
`biomarker
`flagged as
`target
`
`Thmor Type
`Adipose tissue,
`if not available use
`fibroblast (1)
`# of times
`biomarker
`flagged as
`target
`
`FIG. 27A
`
`Adrenal Cortex (18)
`# of times
`biomarker
`flagged as
`target
`
`Adrenal Gland (1)
`# of times
`biomarker
`flagged as
`target
`
`Medulla (15)
`# of times
`biomarker
`flagged as
`target
`
`Appendix (5)
`# of times
`biomarker
`flagged as
`
`
`
`target
`
`3 _—_—_—_—_—_ — —_—_—_—_—_—_— —
`
`12
`
`12 31
`
`1
`
`1
`
`321 14
`
`1 241 1 12 31 13 31 2
`
`1
`
`>—‘>—‘>—‘4;
`
`,_1
`4
`
`2
`
`3
`
`3
`14
`
`5
`
`N\l
`
`2 143
`
`1
`
`1
`
`1
`
`1
`
`1
`
`11
`
`1
`
`1
`
`11
`
`1
`
`4
`
`1 1 7 27
`
`10
`
`1
`
`1 7
`
`14 4
`
`3 4
`
`,_1
`4
`
`2
`
`14
`
`1N
`
`35
`
`3335;
`3233?"
`328%
`.
`a
`.
`o
`0.82% — 0.000
`1.61%)
`0.00%
`4.92% — 0.00% —— 0
`000A)
`0.00%
`— 0.00% — 0.004 ——.
`0.00%
`645%
`0.00% — 0.00%
`484%
`0 00%
`0.00% — 0.00%
`0.00%
`0.82%
`— 0.00% — 0.004
`0.00%
`0.00%
`— 0.00% — 0.00%
`1
`0.62%
`1.61%
`0 82%
`0 00%
`0.00%
`0.00%
`0.00%
`__
`5.74%
`10.00%
`5.59%
`——
`0 00%
`0 00%
`0 00%
`1.64%
`0.00%
`4.97%
`0.00%
`5.74%
`0.00%
`5.59%
`0.00%
`8 20%
`0 00%
`8 70%
`0 00%
`4.92%
`0.00%
`0.62%
`1.61%
`0.82%
`0.00%
`0.62%
`3.23%
`0 00%
`0 00%
`0 62%
`0 00%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`10.00%
`0.62%
`1.61%
`0 82%
`0 00%
`2 48%
`3 23%
`0.00%
`0.00%
`0.00%
`0.00%
`5.74%
`0.00%
`0.00%
`4.84%
`0 00%
`0 00%
`0 00%
`1 61%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0 82%
`0 00%
`1 24%
`1 61%
`3.28%
`0.00%
`3.73%
`0.00%
`0 00%
`0 00%
`0 00%
`0 00%
`3 28%
`10.00%
`1 86%
`1 61%
`0.00%
`0.00%
`0.00%
`0.00%
`0 00%
`0 00%
`0 00%
`0 00%
`2 46%
`10.00%
`5 59%
`4 84%
`0.00%
`10.00%
`1.86%
`3.23%
`3 28%
`0 00%
`8 70%
`1 61%
`0 00%
`0 00%
`0 00%
`0 00%
`0.00%
`0.00%
`0.00%
`1.61%
`0 82%
`10.00%
`3 11%
`6 45%
`3.28%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0 00%
`0 00%
`0 00%
`1 61%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`0.00%
`3.23%
`0 00%
`0 00%
`0 00%
`6 45%
`1.64%
`0.00%
`4.35%
`1.61%
`0.00%
`0.00%
`1.24%
`0.00%
`11.48%
`10.00%
`1 24%
`1 61%
`0.00%
`0.00%
`0.00%
`0.00%
`0.82%
`0.00%
`0.62%
`1.61%
`1 64%
`0 00%
`2 48%
`3 23%
`0.00%
`0.00%
`1.86%
`0.00%
`1.64%
`0.00%
`4.97%
`4.84%
`0 82%
`0 00%
`2 48%
`1 61%
`3.28%
`0.00%
`2.48%
`0.00%
`3.28%
`10.00%
`2.48%
`1.61%
`3 28%
`10.00%
`4 35%
`4 84%
`0.62%
`0.00%
`7.45%
`0.00%
`0.00%
`0.00%
`0.00%
`4.84%
`0 00%
`10.00%
`0 62%
`1 61%
`0.00%
`0.00%
`0.00%
`0.00%
`2.46%
`0.00%
`0.00%
`3.23%
`
`_4.10‘V _ 0.00% _ 0.00% _1
`1.61%
`
`246W: — 0.00%
`0.62% — 0.00%0
`0.00% _ 0.00% _ 0.00% _ 0.00% _ 0.004)
`
`
`
`
`
`4 ,
`
`_1
`
`2 5
`
`11
`
`N
`
`10
`
`3
`
`_ _—_-
`
`,_1
`
`,_1
`
`2
`
`__—_ ‘
`
`-_ —
`
`—_
`
`109
`
`10000%
`
`9
`
`10000%
`
`100400%
`
`10000%
`
`Gene Name (Microarray)
`
`
`
`Gene
`ADA
`AR
`ASNS
`ASNS
`BRCA1
`BRCA2
`CD52
`CDW52
`CES2
`CES2*
`DCK
`DHFR
`DMNT1
`DMNT3A
`DMNT3B
`EGFR
`EPHA2
`ERBB2
`ESRI
`FLT1
`GART
`GNRH1
`HIF1A
`HSP90AA1
`HSPCA
`[L2RA
`KDR
`KIT
`LCK
`MGMT
`MLH1
`MSH2
`NFKBI
`NFKB2
`NFKB 1A
`PD GFC
`PD GFRA
`PD GFRB
`PGR
`PTEN
`PTGS2
`RARA
`RRM1
`RRM2
`RRM2B
`RXRG
`SPARC
`SPARC*
`SRC
`SSTRI
`SSTR2
`SSTR3
`SSTR4
`SSTR5
`TOP1
`TOP2A
`TOP2B
`TYMS
`VDR
`VEGF
`VEGFA
`VHL
`YES 1
`ZAP7
` Total Number of DMA
`Biomarkers Flagged as
`Talget for Tumor Type:
`Samoles
`
`

`

`94444100
`# of times
`biomarker
`flagged as
`target
`42
`27
`
`5 9
`
`62
`1
`
`21
`
`30
`18
`
`28
`
`13
`4
`
`FIG. 27B
`
`Bone if you have it
`if not Cartilage (1)
`# of times
`biomarker
`flagged as
`target
`
`# of times
`biomarker
`flagged as
`target
`000%
`0
`0.00%) ——
`
`Blood Vessel Vain (4)
`# of times
`biomarker
`flagged as
`target
`2
`
`4.359
`
`# of times
`biomarker
`flagged as
`target
`
`7.41%
`
`Bladder (7)
`
`# of times
`biomarker
`flagged as
`
`0
`
`1
`5
`
`10
`29
`18
`22
`
`15
`
`77
`
`12
`23
`
`4
`6
`2
`
`56
`1
`31
`33
`21
`55
`
`15
`
`48
`10
`1
`15
`
`4
`48
`15
`2
`16
`
`32
`42
`12
`74
`27
`23
`26
`34
`18
`29
`67
`1
`15
`
`11
`
`1
`
`6
`1
`2
`2
`
`1
`2
`
`2
`
`
`
`
`
`
`
`2.233;»
`333:?"
`—1133%? ==— 0.00%
`1 —~0 ——~°
`~
`9
`3.70%
`000%
`0
`0.00%
`0.00%) —
`000A)
`0.00% — 00% ——0‘004y 0.00% — 000%
`0.00% — 000g) ——0~004y° 000% — 0.00%
`0.00% — 0.00% — ~
`0°
`‘
`0
`0.00%
`—000A3 0.00%) —
`0.00% — 0001f) — 000%
`0.00% — 0.00%
`000% — 000? — 0‘009"
`000% — 0.00%
`”3%
`6524’ —— ‘°
`000%
`000A)
`0.00%) —
`0.00% — 0001f) — 000%
`0.00% — 0.00%
`617% — 000? — 0‘009"
`000% — 0.00%
`0.00% — 0.00% — ~
`0°
`‘
`0
`0.00%
`—000A3 9.0% —
`4.33% — 0.00% — ~
`0
`9099
`6.67%
`1
`3.70%)
`1
`4.94% — 0.000%) — a
`—0009
`3.33%
`2
`7.41%)
`.
`0
`370%
`6524’ —— °
`333%
`1
`000A)
`0.00%) —
`1.23% — 00% ——0‘004y 0.00%
`333%
`3.47% — 000g) ——0~004y° 000% — 0.00%
`0.00% — 0.00% — ~
`0°
`‘
`0
`0.00%
`—000A3 0.00%) —
`0.00% — 0.00% — ~
`0
`0009
`6.67%
`2
`7.41%)
`000% — 000? — 0009
`909%
`6.67%
`1
`494%
`”74’ —— ‘°
`000%
`000A)
`0.00%) —
`0.00% — 00% ——0‘004y1
`9.09%
`667%
`741%
`“7? — 0‘009"
`000% — 0.00%
`“7% — 0‘00? —— ‘

`000%
`000A)
`0.00%) —
`0.00% — 0001f) — 000V
`000% — 0.00%
`1
`0.00% — 000g) — ~

`000% — 0.00%
`000%
`”74’ —— °
`000%
`000A)
`0.00%) —
`0.00% — 0001f) — 000V
`000% — 0.00%
`0.00% — 0.00% — .
`04
`9090
`3.33%
`2
`7.41%)
`1
`”1% — 0‘00? —— °
`000%
`000A)
`0.00%) —
`1.23% — 0.001%) — 000%
`0.00% — 0.00%
`000% — 000? — 0‘009"
`000%
`3.33%
`247%
`87004 — ‘
`9°
`—0‘009
`333%
`2
`7.41%)
`.
`0
`0.00%
`6.522) — a
`9099
`3.33%
`2
`7.41%)
`2.47%
`6.521%) — 000V
`000% — 0.00%
`000% — 0‘00? —— ‘

`667%
`2
`000A)
`0.00%) —
`0.00%
`217(4) ——0‘004y1
`9.09%
`667%
`000%
`435? — 0‘009"
`000% — 0.00%
`0.00% — 0.000%) — ~
`0°
`‘
`0
`0.00%
`—000A3 0.00%) —
`1.23% — 0004; — ~
`0
`000W — 0.00%
`2
`7.41%)
`2.47%
`2.171%) — 000V
`000% — 0.00%
`0.00% — 0.00% — ~
`0°
`‘
`0
`0.00%
`—000A3 0.00%) —
`0.00% — 0001f) — 000V
`000% — 0.00%
`000%
`“7? — ‘
`9"
`000% — 0.00%
`1
`3.70%)
`0.00% — 0.00% — 0
`0
`0.00%
`—000A3 0.00%) —
`0.00% — 0.00% — ~
`0
`9099
`6.67%
`1
`3.70%)
`1
`2.47%
`6.521%) — 000V
`000% — 0.00%
`0.00% — 0.00% — ~
`0°
`‘
`0
`0.00%
`—000A3 0.00%) —
`0.00%
`6521?) — 000V
`000% — 0.00%
`247% — 000? — ‘
`9"
`—000%— 0.00%
`2
`2
`7.41%)
`.
`0
`000%
`43504 — o
`0009 — 0.00%
`1
`3.70%)
`617%
`6‘52? — 0009
`0.00% — 0.00%
`5
`247% — 000? — 0‘009"
`000%
`3.33%
`2
`000% — 00004 — ‘
`9°
`0009
`3.33%
`1
`3.70%)
`8.64%
`4.351%) — 000V
`000% — 0.00%
`7
`7.41%
`2.17? — ~
`0°
`90W
`3.33%
`6
`2
`7.41%)
`1
`“7% — 0‘00? —— °
`000%
`2
`000A)
`0.00%) —
`0.00% — 00% ——0‘004y1
`9.09%
`667%
`4.94% — 0.001%) — 0‘00;
`000% — 0.00%
`4
`000% — 00004 — ‘
`9°
`—0‘009
`667%
`2
`7.41%)
`.
`0
`123%
`6‘52? — 0009
`0.00% — 0.00%
`1
`123% — 000? — 0‘009"
`000% — 0.00%
`1
`1.23%
`4354 — ~
`0°
`0‘000 — 0.00%
`1
`0
`0.00% — 0.00%)
`,
`N334403331000029 11
`1000043100009
`
`04444045)
`
`4.84%
`0 00%
`1.61%
`0.00%
`1 61%
`0 00%
`0.00%
`0.00%
`1 61%
`0 00%
`4.84%
`1.61%
`1 61%
`0 00%
`3.23%
`1.61%
`0.00%
`0 00%
`0.00%
`0.00%
`3.23%
`0 00%
`6 45%
`1.61%
`1.61%
`0 00%
`0 00%
`3.23%
`0.00%
`4 84%
`0 00%
`0.00%
`1.61%
`3 23%
`4 84%
`0.00%
`1.61A
`4.84%
`0 00%
`0.00%
`4.84%
`0.00%
`0 00%
`0 00%
`0.00%
`0.00%
`4 84%
`0 00%
`1.61%
`1.61%
`0 00%
`4.84
`1.61%
`4.84%
`0 00%
`1 61%
`3.23%
`0.00%
`8.06%
`0 00%
`1.61%
`1.61%
`0.00%
`0 00%
`100.00'
`
`# of times
`biomarker
`flagged as
`
`r—w—‘w
`
`r—‘N
`
`r—‘r—‘Jk
`
`>—‘N>—‘
`
`W W
`
`W N
`
`3.63%
`2.33%
`0.43%
`0.00%
`0 78%
`5 35%
`0.09%
`0.00%
`1 81%
`0 00%
`2.59%
`1.55%
`0.17
`0 69%
`1.12%
`0.35%
`0.00%
`0.86%
`2.50%
`1.55%
`1.90%
`0 00%
`1 30%
`0.60%
`0.60%
`0 00%
`1 04%
`1.99%
`0.00%
`4.84%
`0.09%
`2.68%
`2.85%
`1.81%
`4.75%
`0.09%
`0.43%
`4.15%
`0.86%
`0.09%
`1.30%
`0.00%
`0 35%
`4 15%
`1.30%
`0.17%
`1 38%
`0 00%
`2.76%
`3.63%
`1.04%
`6.39%
`2.33%
`1.99%
`2.25%
`2.94%
`1.55%
`2.50%
`5.79%
`0.09%
`1.30%
`0.00%
`0.95%
`0 00%
`100.00' 0
`
`1158
`
`82
`
`

`

`FIG. 27C
`
`Dendritic cells can be
`found in skin, the spleen,
`lymph node. Let’s get
`Difficult origin to define.
`Mike Bittner’s take on site
`Endometrium (3)
`Try skeletal muscle (1)
`of origin (1)
`Colon Sigmoid (1)
`Colon (66)
`Cervix (10)
`# of times
`# of times
`# of times
`# of times
`# of times
`# of times
`biomarker
`biomarker
`biomarker
`biomarker
`biomarker
`biomarker
`biomarker
`flagged as
`flagged as
`flagged as
`flagged as
`flagged as
`flagged as
`flagged as
`target
`target
`target
`target
`target
`target
`target
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`————————————-_
`u———————————-_
`———————————-—
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`—————————————
`———————-_—————
`—————————————
`—————————————
`————————————-
`—————————————
`—————————————
`—————————————
`—————————-———
`———————————

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.

We are unable to display this document.

HTTP Error 500: Internal Server Error

Refresh this Document
Go to the Docket